TxCell's treatments are innovative cellular therapies based on autologous specific antigen regulatory type 1 T lymphocytes (Tr1). These treatments represent a vast array of different suppressive actions that could not be mimicked by conventional medications.  By these multiple mechanisms of actions, it is likely that Tr1 cells activity will dampen the inflammatory immune reponse and re-equilibrate the tissue microenvironement in a tolerogenic state, leading to a restoration of the tissue homeostasis.